4SC-205 / 4SC 
Welcome,         Profile    Billing    Logout  
 5 Diseases   0 Trials   10 News 
  • ||||||||||  Xtandi (enzalutamide) / Pfizer, Astellas, Bausch Health, 4SC-205 / 4SC
    [VIRTUAL] KIF11-AR dual inhibition: a novel strategy to reverse endocrine therapy resistance in CRPC (EACR 2021) -  May 30, 2021 - Abstract #EP-772; Author: L. SUAREZ 1; M. Olivan1; A. Zucchiatti2; N. Masia1; M. Masanas3; A. Aytes4; A. Villanueva5; M. Segura3; J. Morote1; A. Santamaria1; Presentation Time: June 09, 2021; -   
    These led us to hypothesize that KIF11 and the AR form a positive feedback loop in PCa promoting cell proliferation, the development of CRPC and therapy resistance. Furthermore, we demonstrate that KIF11 inhibition effectively enhances the sensitivity of CRPC cells and reverses enzalutamide resistance both, in vitro and in vivo Conclusion Altogether, we conclude that KIF11 overexpression plays an important role in the progression of CRPC and therapy resistance and we propose that a dual inhibition of the AR pathway and KIF11 could enhance the sensitivity of prostate tumors to enzalutamide giving a good rationale for a combination therapy for the treatment of CRPC patients
  • ||||||||||  Xtandi (enzalutamide) / Pfizer, Astellas, Bausch Health, 4SC-205 / 4SC
    [VIRTUAL] KIF11-AR dual inhibition: a novel strategy to reverse endocrine therapy resistance in CRPC (EACR 2021) -  May 30, 2021 - Abstract #EP-772; Author: L. SUAREZ 1; M. Olivan1; A. Zucchiatti2; N. Masia1; M. Masanas3; A. Aytes4; A. Villanueva5; M. Segura3; J. Morote1; A. Santamaria1; Presentation Time: June 10, 2021; -   
    These led us to hypothesize that KIF11 and the AR form a positive feedback loop in PCa promoting cell proliferation, the development of CRPC and therapy resistance. Furthermore, we demonstrate that KIF11 inhibition effectively enhances the sensitivity of CRPC cells and reverses enzalutamide resistance both, in vitro and in vivo Conclusion Altogether, we conclude that KIF11 overexpression plays an important role in the progression of CRPC and therapy resistance and we propose that a dual inhibition of the AR pathway and KIF11 could enhance the sensitivity of prostate tumors to enzalutamide giving a good rationale for a combination therapy for the treatment of CRPC patients
  • ||||||||||  Xtandi (enzalutamide) / Pfizer, Astellas, Bausch Health, 4SC-205 / 4SC
    [VIRTUAL] KIF11-AR dual inhibition: a novel strategy to reverse endocrine therapy resistance in CRPC (EACR 2021) -  May 30, 2021 - Abstract #EP-772; Author: L. SUAREZ 1; M. Olivan1; A. Zucchiatti2; N. Masia1; M. Masanas3; A. Aytes4; A. Villanueva5; M. Segura3; J. Morote1; A. Santamaria1; Presentation Time: June 11, 2021; -   
    These led us to hypothesize that KIF11 and the AR form a positive feedback loop in PCa promoting cell proliferation, the development of CRPC and therapy resistance. Furthermore, we demonstrate that KIF11 inhibition effectively enhances the sensitivity of CRPC cells and reverses enzalutamide resistance both, in vitro and in vivo Conclusion Altogether, we conclude that KIF11 overexpression plays an important role in the progression of CRPC and therapy resistance and we propose that a dual inhibition of the AR pathway and KIF11 could enhance the sensitivity of prostate tumors to enzalutamide giving a good rationale for a combination therapy for the treatment of CRPC patients
  • ||||||||||  Xtandi (enzalutamide) / Pfizer, Astellas, Bausch Health, 4SC-205 / 4SC
    [VIRTUAL] KIF11-AR dual inhibition: a novel strategy to reverse endocrine therapy resistance in CRPC (EACR 2021) -  May 30, 2021 - Abstract #EP-772; Author: L. SUAREZ 1; M. Olivan1; A. Zucchiatti2; N. Masia1; M. Masanas3; A. Aytes4; A. Villanueva5; M. Segura3; J. Morote1; A. Santamaria1; Presentation Time: June 12, 2021; -   
    These led us to hypothesize that KIF11 and the AR form a positive feedback loop in PCa promoting cell proliferation, the development of CRPC and therapy resistance. Furthermore, we demonstrate that KIF11 inhibition effectively enhances the sensitivity of CRPC cells and reverses enzalutamide resistance both, in vitro and in vivo Conclusion Altogether, we conclude that KIF11 overexpression plays an important role in the progression of CRPC and therapy resistance and we propose that a dual inhibition of the AR pathway and KIF11 could enhance the sensitivity of prostate tumors to enzalutamide giving a good rationale for a combination therapy for the treatment of CRPC patients
  • ||||||||||  4SC-205 / 4SC
    [VIRTUAL] A Phase 1 Dose-Escalation Study of LH031, a Kinesin Spindle Protein Inhibitor, in Patients with Refractory/Resistance Multiple Myeloma (ASH 2020) -  Nov 5, 2020 - Abstract #1386; Author: Zhongjun Xia, MD, PhD1; Su Li2; Xiaoqin Chen, MD, PhD3; Weida Wang, MD, PhD4; Yan Song5; Presentation Time: December 05, 2020; 07:00-15:30   
    It demonstrated that the elimination rate of LH031 in Chinese patients was slower than Caucasian. The monotherapy showed some benefit to RRMM, Phase 2 clinical trials are being planned to include various combination therapies with existing treatments (e.g. lenalidomide, dexamethasone, bortezomib) for MM to benefit more potential refractory/resistance MM patients.